Pharmaceuticals
Our global Pharmaceuticals portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. We have received 17 new pharmaceutical product approvals in the US since 2000, the most of any pharmaceutical company.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Click on the product link where available to display complete product information. Please note that some product links are intended for US residents only.
A-Z
A C D E F G L M N P R S T V X Z
Lamisil
Fungal infections of the skin and nails
Visit www.lamisil.com (US residents only)
Lescol/Lescol XL
Hypercholesterolemia and mixed dyslipidemia
Visit www.lescolxl.com (US residents only)
Lotensin/ Cibacen
Hypertension
Lotensin HCT/ Cibadrex
Hypertension
Lotrel
Hypertension
Visit www.lotrel.com (US residents only)
Lucentis (ranibizumab)
Wet form of age-related macular degeneration (AMD), a leading cause of blindness
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
Latest news
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.